OTC Markets OTCPK - Delayed Quote ? USD PaxMedica, Inc. (PXMD) Follow Compare 0.0995 +0.0295 +(42.14%) At close: 3:46 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations PaxMedica Secures Immediate Exercise of Warrants TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the ... ACCESSWIRE ? 2 months ago PXMD +42.14% PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological ... ACCESSWIRE ? 2 months ago PXMD +42.14% PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal t GlobeNewswire ? 6 months ago PXMD +42.14% PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains GlobeNewswire ? 6 months ago PXMD +42.14% PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica (NASDAQ: PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, takes center s GlobeNewswire ? 6 months ago PXMD +42.14% PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east Africa. The request seeks emergency access to the Company’s recently completed registration batches of PAX-101 (IV suramin) to address the critic GlobeNewswire ? 6 months ago PXMD +42.14% PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drug TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutica GlobeNewswire ? 7 months ago PXMD +42.14% PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), which is currently planned for Q4 202 GlobeNewswire ? 7 months ago PXMD +42.14% PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community. Click here to view the presentation. The new presentation, available GlobeNewswire ? 8 months ago PXMD +42.14% IBN Highlights PaxMedica's Video Release on Transformative ASD Study LOS ANGELES, CA - (NewMediaWire) - January 18, 2024 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.In a significant development for the neurological disor... NewMediaWire ? 9 months ago PXMD +42.14% PaxMedica on Promising Path to Address Unmet ASD Needs LOS ANGELES, CA - (NewMediaWire) - January 17, 2024 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmac... NewMediaWire ? 10 months ago PXMD +42.14% PaxMedica Files 8-K Following Nasdaq Compliance Achievement LOS ANGELES, CA - (NewMediaWire) - December 22, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.In a significant corporate update, PaxMedica (NASDAQ: ... NewMediaWire ? 10 months ago PXMD +42.14% PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline LOS ANGELES, CA - (NewMediaWire) - December 19, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.The CDC estimates 1 out of 36 children in the United S... NewMediaWire ? 10 months ago PXMD +42.14% PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report LOS ANGELES, CA - (NewMediaWire) - December 12, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.PaxMedica Inc. (NASDAQ: PXMD), a biopharmaceutical com... NewMediaWire ? 11 months ago PXMD +42.14% PaxMedica CEO Featured in Just-Released Fireside Chat Video LOS ANGELES, CA - (NewMediaWire) - December 08, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.PaxMedica (NASDAQ: PXMD), a biopharmaceutical company ... NewMediaWire ? 11 months ago PXMD +42.14% PaxMedica Closes Public Offering of Approximately $7M, Continues Pursuing ASD Pipeline LOS ANGELES, CA - (NewMediaWire) - December 07, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.PaxMedica's total gross proceeds from the offering, be... NewMediaWire ? 11 months ago PXMD +42.14% PaxMedica Releases Fireside Chat Video with CEO Howard Weisman TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman ... ACCESSWIRE ? 11 months ago PXMD +42.14% PaxMedica Closes on Public Offering Reaching Estimated $7M LOS ANGELES, CA - (NewMediaWire) - December 01, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.PaxMedica (NASDAQ: PXMD), a biopharmaceutical company ... NewMediaWire ? 11 months ago PXMD +42.14% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return PXMD S&P 500 YTD -86.86% +25.15% 1-Year -87.56% +31.54% 3-Year -99.91% +47.11%
